Glaucoma Research Foundation

Annual Gala to 'Celebrate' with 'The Cure in Sight'Glaucoma 360, a three-day event held by the Glaucoma Research Foundation (GRF), launched its seventh year Thursday night with the Glaucoma 360 Annual Gala that attracted more than 400 people to the Palace Hotel in San Francisco.
Glaucoma Symposia aim to 'Educate' with 2 sessionsGlaucoma 360, a three-day event organized by the Glaucoma Research Foundation (GRF) will move into its final day on Saturday with the Glaucoma Symposium. The focus will shift from "Innovate" to "Educate." Two continuing medical education sessions are-one for ophthalmologists in the morning and another for optometrists in the afternoon.
New Horizons Forum breaks ground to 'Innovate'Glaucoma 360, a three-day event being held here by the Glaucoma Research Foundation (GRF), will move from its "Celebrate" phase with Annual Gala on Thursday into its "Innovate" phase with the New Horizons Forum set for today. This event is a full day of presentations, panels, and discussions featuring leaders from start-up companies, industry executives, ophthalmic experts, venture capitalists, and the FDA.
Glaucoma 360 annual meeting will celebrate, innovate, educate in 2018
Teleglaucoma redefining role in future of blindness prevention'Teleglaucoma’ is feasible and can play a major role in blindness prevention. Telemedicine and teleglaucoma are going to be an important part of how physicians take care of patients in the United States and worldwide.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Aerie’s focus on therapies that address cause of vision lossAerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
B + L places focus on innovation in pharma, surgical, vision careBausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.
Novartis Alcon changes build better platform for ophthalmologyAlcon Laboratories pharmaceutical products have been moved into the Novartis Pharmaceutical Division. The switch means a sharper focus on research and development in ophthalmology as well as better access to Norvartis’ patient services and support capabilities.
New technologies on horizon to redefine drug deliveryGlaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.